We are live on ! Find out more
BIO icon

Bio-Rad Laboratories Class A

380.12 USD
-5.99
1.55%
At close Updated Sep 8, 4:00 PM EDT
Pre-market
After hours
380.12
0.00
0%
1 day
-1.55%
5 days
-2%
1 month
7.21%
3 months
30.49%
6 months
40.04%
Year to date
24.52%
1 year
30.9%
5 years
-53.28%
10 years
137.03%
 

About: Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Employees: 7,450

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 42.9%
Neutral 50%
Negative 7.1%
Positive
Zacks Investment Research
5 days ago
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?
Neutral
Business Wire
9 days ago
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo's 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relati.
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference
Positive
Zacks Investment Research
18 days ago
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?
BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?
Positive
Zacks Investment Research
19 days ago
Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?
BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.
Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?
Neutral
Zacks Investment Research
29 days ago
Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock
Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock
Negative
MarketBeat
1 month ago
Bio-Rad Laboratories Q2 Earnings Call Highlights
Bio-Rad Laboratories NYSE: BIO reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier on a reported basis and down 1.9% on a currency-neutral basis, as continued softness in academic research markets weighed on its Life Science segment.
Bio-Rad Laboratories Q2 Earnings Call Highlights
Neutral
Seeking Alpha
1 month ago
Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
Bio-Rad Laboratories (BIO) Beats Q2 Earnings Estimates
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.34 per share. This compares to earnings of $2.61 per share a year ago.
Bio-Rad Laboratories (BIO) Beats Q2 Earnings Estimates
Neutral
Business Wire
1 month ago
Bio-Rad Reports Second-Quarter 2026 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR.
Bio-Rad Reports Second-Quarter 2026 Financial Results
Neutral
Business Wire
1 month ago
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2026 on Tuesday, August 4, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
Price charts implemented using Lightweight Charts™